| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director, 10% Owner | Director +2 more
43 companies
Ra Capital Management, L.P. is a Director, 10% Owner at WVE with holdings across 43 companies. Recent SEC Form 4 filings include 13 buys and 0 sells.
Estimated insider holdings value: $3467.7M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2023 | SPRY Ars Pharmaceuticals, Inc. | Director | Buy | 2,700,000 | $3.03 | $8,183,525.74 | +19.0% | +37.3% | +302.5% | |
| Aug 29, 2023 | SPRY Ars Pharmaceuticals, Inc. | Director | Buy | 3,750,000 | $6.20 | $23,250,000.00 | +178.0% | -34.0% | +93.8% | |
| Aug 18, 2023 | ANTX An2 Therapeutics, Inc. | 10% Owner | Buy | 1,777,778 | $9.00 | $16,000,002.00 | +52.9% | +47.4% | -91.2% | |
| Jul 21, 2023 | ABOS Acumen Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 5,161,290 | $7.75 | $39,999,997.50 | +65.5% | -52.8% | -61.2% | |
| Jul 19, 2023 | JANX Janux Therapeutics, Inc. | Director, 10% Owner | Buy | 495,008 | $12.46 | $6,167,799.68 | +6.5% | -38.2% | +239.2% | |
| Jul 5, 2023 | BDTX Black Diamond Therapeutics, Inc. | Director | Buy | 935,850 | $5.00 | $4,679,250.00 | +41.1% | -44.4% | -8.0% | |
| Feb 14, 2023 | MLYS Mineralys Therapeutics, Inc. | Director | Buy | 1,250,000 | $16.00 | $20,000,000.00 | +64.8% | -10.1% | -19.3% | |
| Jan 20, 2023 | FULC Fulcrum Therapeutics, Inc. | 10% Owner | Buy | 1,923,076 | $13.00 | $24,999,988.00 | +19.9% | -80.4% | -45.2% | |
| Jan 6, 2023 | HOWL Werewolf Therapeutics, Inc. | Director, 10% Owner | Buy | 1,853,000 | $2.21 | $4,095,130.00 | +48.2% | +11.1% | +138.2% | |
| Jan 4, 2023 | FULC Fulcrum Therapeutics, Inc. | 10% Owner | Buy | 180,703 | $7.28 | $1,314,805.84 | +0.9% | -68.4% | -10.5% |